## UNITED STATES PATENT AND TRADEMARK OFFICE

## BEFORE THE PATENT TRIAL AND APPEAL BOARD

# ACTAVIS LLC *Petitioner,*

v.

ABRAXIS BIOSCIENCE, LLC Patent Owner

> Case IPR2017-01101 Case IPR2017-01103 Case IPR2017-01104

U.S. Patent 7,820,788 U.S. Patent 7,923,536 U.S. Patent 8,138,229

# JOINT MOTION TO TERMINATE PURSUANT TO 35 U.S.C. § 317 AND 37 C.F.R. § 42.74

DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>. Pursuant to 35 U.S.C. § 317, 37 C.F.R. §§ 42.72 and 42.74, and the Board's authorization of January 26, 2018, Petitioner Actavis LLC ("Petitioner" or "Actavis") and Patent Owner Abraxis Bioscience, LLC ("Patent Owner") jointly move to terminate the present *inter partes* review proceeding in light of Patent Owner and Petitioner's settlement of their disputes.

Petitioner and Patent Owner are concurrently filing a true and complete copy of their confidential written settlement materials (with exhibits, Confidential Exhibit 2066) in connection with this matter as required by statute. Petitioner and Patent Owner certify that there are no other agreements or understandings, oral or written, between the parties, including any collateral agreements, made in connection with, or in contemplation of, the termination of the present proceeding. A joint request to treat the settlement materials (with exhibits, Confidential Exhibit 2066) as business confidential information kept separate from the file of the involved patent pursuant to 35 U.S.C. § 317(b) is being filed concurrently.

### LEGAL STANDARD

An *inter partes* review proceeding "shall be terminated with respect to any petitioner upon the joint request of the petitioner and the patent owner, unless the Office has decided the merits of the proceeding before the request for termination is filed." 35 U.S.C. § 317(a). A joint motion to terminate generally "must (1) include a brief explanation as to why termination is appropriate; (2) identify all

parties in any related litigation involving the patents at issue; (3) identify any related proceedings currently before the Office, and (4) discuss specifically the current status of each such related litigation or proceeding with respect to each party to the litigation or proceeding." *Heartland Tanning, Inc. v. Sunless, Inc.*, IPR2014-00018, Paper No. 26, at \*2 (P.T.A.B. July 28, 2014).

#### ARGUMENT

Termination of the present *inter partes* review proceeding is appropriate because (1) Petitioner and Patent Owner have settled their disputes and have agreed to terminate the proceeding, (2) the Office has not yet decided the merits of the proceeding, and (3) public policy favors the termination.

*First*, the parties' settlement completely resolves the controversy between Patent Owner and Petitioner relating to the '788, '536, and '229 patents. Actavis, which is the real party in interest in the present proceeding, was named defendant in *Abraxis BioScience, LLC, et al. v. Actavis LLC*, No. 16-1925 (D.N.J.). On January 26, 2018, the parties filed a Consent Judgment requesting that all claims against Actavis and all counterclaims by Actavis be dismissed with prejudice.

*Second*, the Office has not decided the merits of the proceeding. Although the Board has instituted trial (Paper 7), the proceeding is still in the briefing stage and there is no determination of whether an oral hearing will occur. A joint stipulation to extend Due Dates 1-2 was filed on January 8, 2018. (Paper 20). *Third*, public policy favors the termination. As recognized by the rules of practice before the Board:

There are strong public policy reasons to favor settlement between the parties to a proceeding. The Board will be available to facilitate settlement discussions, and where appropriate, may require a settlement discussion as part of the proceeding. The Board expects that a proceeding will terminate after the filing of a settlement agreement, unless the Board has already decided the merits of the proceeding.

Patent Office Trial Practice Guide, Fed. Register, Vol. 77, No. 157 at 48768

(Aug. 14, 2012). Moreover, no public interest or other factors militate against termination of this proceeding.

As to the remaining *Heartland Tanning* requirements, Exhibit A identifies each district court litigation, and all petitions for *Inter Partes* Review that have been filed against the '788, '536, and '229 patents or other related patents, and discusses the status of each case.

### **CONCLUSION**

For the foregoing reasons, Petitioner and Patent Owner jointly and respectfully request that the instant proceeding be terminated.

Respectfully submitted,

/Samuel S. Park / Samuel S. Park, (Reg. No. 59,656) George C. Lombardi Charles B. Klein Kevin E. Warner Eimeric Reig-Plessis WINSTON & STRAWN LLP 35 W. Wacker Drive Chicago, IL 60601 312-558-7931 AbraxaneIPR@winston.com

*Counsel for Petitioner Actavis LLC* 

DOCKF

RM

<u>/Christopher J. Harnett/</u> Christopher J. Harnett (Reg. No. 35,538) Anthony M. Insogna (Reg. No. 35,203) Cary Miller, Ph.D. (Reg. No. 54,708) Lisamarie LoGiudice, Ph.D. (Reg. No. 71,047) JONES DAY 250 Vesey Street New York, NY 10281-10147 Tel: (212) 326-3939 Fax: (212)-755-7306 charnett@jonesday.com aminsogna@jonesday.com llogiudice@jonesday.com

F. Dominic Cerrito (Reg. No. 38,100) Andrew S. Chalson (pro hac vice) Frank C. Calvosa (Reg. No. 69,064) Daniel Wiesner (pro hac vice) QUINN EMANUEL URQUHART & SULLIVAN, LLP 51 Madison Avenue, 22nd Floor New York, NY 10010 General Tel: (212) 849-7000 Direct Tel: (212) 849-7450 Fax: (212) 849-7450 Fax: (212) 849-7100 nickcerrito@quinnemanuel.com andrewchalson@quinnemanuel.com frankcalvosa@quinnemanuel.com

Counsel for Patent Holder Abraxis Bioscience, LLC

# DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

# API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

# E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.